title: Pharmacological compliance and acceptability of lansoprazole orally disintegrating tablets in primary care.
abstract: OBJECTIVE
  To evaluate the pharmacological compliance of patients treated with lansoprazole orally disintegrating tablets (LODT) in Primary Care (PC) and their acceptability of this formulation.
  
  
  METHODS
  A multicenter, observational, cross-sectional study involving 433 PC physicians that included 433 patients aged at least 18 years, either diagnosed with gastroesophageal reflux disease (GERD) or taking LODT to prevent NSAID-induced gastric ulcers. Compliance with LODT treatment was assessed with the Haynes-Sackett self-reported test. Acceptability was based on global patient assessment, rating the drug's organoleptic characteristics and properties recorded with a self-administered 15-item ad hoc questionnaire with 2 and 5-point Likert-type scales.
  
  
  RESULTS
  423 patients (mean age 50.6 years, SD = 13.4) were evaluable for the main endpoint. Of these, 57.16% were men and 53.5% were treated with 30 mg doses of LODT for an average of 37.8 days (SD = 35.5). Compliance was achieved by 92.4% of the patients, mean percentage of compliance was 93.3. Demographical and clinical variables had no effect on compliance. Treatment with LODT was assessed as 'acceptable' or 'highly acceptable' by 91.7% of the sample. One adverse reaction, not serious, was reported by one patient (0.2%).
  
  
  CONCLUSIONS
  In this observational study, compliance with lansoprazole orally disintegrating tablets was very high. Patients reported that this formulation improved their compliance. LODT was clearly preferred to previous medication and the drug was well tolerated.
authors.affiliation: Health Center La Orden, Huelva, Spain. emarquezc@papps.org
authors.forename: E
authors.initials: E
authors.lastname: Márquez-Contreras
authors.forename: V
authors.initials: V
authors.lastname: Gil
authors.forename: J
authors.initials: J
authors.lastname: López
authors.forename: M J
authors.initials: MJ
authors.lastname: Plazas
authors.forename: J
authors.initials: J
authors.lastname: Heras
authors.forename: J
authors.initials: J
authors.lastname: Galván
authors.forename: J
authors.initials: J
authors.lastname: Porcel
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects; D003430:Cross-Sectional Studies; D005260:Female; D005764:Gastroesophageal Reflux / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D010342:Patient Acceptance of Health Care; D010349:Patient Compliance; D011320:Primary Health Care; D054328:Proton Pump Inhibitors / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D011795:Surveys and Questionnaires; D013607:Tablets
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000894:Anti-Inflammatory Agents, Non-Steroidal; D054328:Proton Pump Inhibitors; D013607:Tablets; D064747:Lansoprazole